Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
- PMID: 25918956
- DOI: 10.1097/QCO.0000000000000161
Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Abstract
Purpose of review: Respiratory syncytial virus (RSV) remains an important cause of serious and sometimes fatal acute lower respiratory tract disease in infants, yet no effective antiviral treatment or vaccine for the prevention of RSV in early life is available. Vaccination of women during pregnancy is considered to be the most plausible strategy to provide direct RSV antibody protection to young infants during a period of greatest vulnerability.
Recent findings: Interest in the development of RSV vaccines for immunization of women during pregnancy is high. Numerous studies are underway to better understand the epidemiology and impact of RSV disease in pregnant women and infants, as well as the role of maternal antibodies in the protection of infants against early and severe RSV disease, to identify and measure serologic correlates of protection to RSV in infants and develop well tolerated and immunogenic RSV vaccines for pregnant women.
Summary: Studies of RSV vaccination in pregnancy are in progress, making maternal vaccination a realistic intervention for the protection of young infants against RSV disease in the near future. Maternal immunization with an immunogenic vaccine has the potential to substantially impact the morbidity and mortality of RSV-associated lower respiratory tract illness in infants worldwide.
Similar articles
-
Immunopathology of RSV infection: prospects for developing vaccines without this complication.Rev Med Virol. 2007 Jan-Feb;17(1):5-34. doi: 10.1002/rmv.518. Rev Med Virol. 2007. PMID: 17004293 Review.
-
Passive and active immunization against respiratory syncytial virus for the young and old.Expert Rev Vaccines. 2017 Jul;16(7):1-13. doi: 10.1080/14760584.2017.1333425. Epub 2017 Jun 7. Expert Rev Vaccines. 2017. PMID: 28525961 Review.
-
Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy.Neonatology. 2024;121(3):271-282. doi: 10.1159/000536031. Epub 2024 Jan 29. Neonatology. 2024. PMID: 38286126 Free PMC article.
-
Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs.Vaccine. 2016 Jan 4;34(2):261-269. doi: 10.1016/j.vaccine.2015.11.029. Epub 2015 Nov 24. Vaccine. 2016. PMID: 26616551
-
In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.J Virol. 2017 Oct 13;91(21):e00851-17. doi: 10.1128/JVI.00851-17. Print 2017 Nov 1. J Virol. 2017. PMID: 28794038 Free PMC article.
Cited by
-
Immunization in Canada: Update for 2015.J Can Chiropr Assoc. 2016 Mar;60(1):6-12. J Can Chiropr Assoc. 2016. PMID: 27069261 Free PMC article. No abstract available.
-
Antibody response to respiratory syncytial virus infection in children <18 months old.Hum Vaccin Immunother. 2016 Jul 2;12(7):1700-6. doi: 10.1080/21645515.2016.1145847. Epub 2016 Feb 22. Hum Vaccin Immunother. 2016. PMID: 26901128 Free PMC article.
-
Dysfunctional labor: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.Vaccine. 2017 Dec 4;35(48 Pt A):6538-6545. doi: 10.1016/j.vaccine.2017.01.050. Vaccine. 2017. PMID: 29150059 Free PMC article. No abstract available.
-
Maternal Effects of Respiratory Syncytial Virus Infection during Pregnancy.Emerg Infect Dis. 2015 Nov;21(11):1951-5. doi: 10.3201/eid2111.150497. Emerg Infect Dis. 2015. PMID: 26485575 Free PMC article.
-
Determinants of early life immune responses to RSV infection.Curr Opin Virol. 2016 Feb;16:151-157. doi: 10.1016/j.coviro.2016.01.003. Epub 2016 Mar 15. Curr Opin Virol. 2016. PMID: 26986236 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
